The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is the current standard first-line therapy for patients with metastatic non–small cell lung cancer (NSCLC) ...

Qualitative responses from individuals involved in the resource-limited pediatric oncology centers mentioned above reveal key enablers for the implementation of QI initiatives. 12 First, the alignment ...

Background: Effective treatment options remain an unmet need for patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). Combination ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States This is a retrospective, ...

Cancer treatment has evolved significantly, with a growing recognition that high-quality care extends beyond treating the disease alone. Multiple guidelines emphasize the need for comprehensive person ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

In the discovery cohort, read mapping to intratumoral Escherichia was associated with significantly longer OS (16 v 11 months; hazard ratio, 0.73 [95% CI, 0.59 to 0.92]; P = .0065) in patients treated ...

Early-stage, triple-negative breast cancer (TNBC) is the most challenging breast cancer (BC) subtype to treat, characterized by a higher histologic grade, resulting in relatively early and high ...

PURPOSEAxicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little ...

The therapeutic potential of PD-1/PD-L1 inhibition has led to the development of multiple immune checkpoint inhibitors (ICIs). 1 Clinical outcomes with PD-(L)1 inhibitors have been positively ...

Background: Patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC) often experience disease relapse even after receiving standard-of-care treatment, e.g. induction chemotherapy ...